In order to test whether the RES and/or FGF1 treatment could affect the efficacy of DOX for inhibiting tumor cell proliferation, we utilized the CCK-8 assay to ascertain the viability of HepG2 cells. The gene discussed is FGF1; the disease is neoplasm.